HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Comparison of oral falecalcitriol and intravenous calcitriol in hemodialysis patients with secondary hyperparathyroidism: a randomized, crossover trial.

AbstractBACKGROUND:
Falecalcitriol is a novel vitamin D analog, which has a greater potential to suppress parathyroid hormone (PTH) and a longer half-life. There are few studies to compare clinical effects of oral falecalcitriol treatment with those of intravenous calcitriol treatment.
METHODS:
Twenty-one patients with moderate to severe SHPT were included in a random 2 x 2 crossover trial with the two vitamin D analogs (12 weeks for each treatment). The primary endpoint measure was a decrease in serum intact PTH (iPTH) level, and the secondary outcome measures included changes in serum calcium (Ca), phosphate (P), and metabolic bone marker levels.
RESULTS:
Both treatments decreased iPTH and whole PTH (wPTH) levels by similar degrees (iPTH, -200.1 +/- 107.0 with falecalcitriol vs. -200.8 +/- 114.9 pg/ml with calcitriol, p = 0.9895; wPTH, -137.1 +/- 73.1 with falecalcitriol vs. -120.4 +/- 81.1 pg/ml with calcitriol, p = 0.5603). Serum Ca, P, and Ca x P product levels at the end of each treatment were comparable and the frequencies of hypercalcemia and hyperphosphatemia were also similar during each treatment period. Although intravenous calcitriol treatment significantly changed intact osteocalcin and cross-linked N-telopeptide of type I collagen after 12 weeks, oral falecalcitriol treatment did not change any bone metabolic marker level.
CONCLUSION:
The present study showed that oral falecalcitriol treatment is effective for PTH suppression, and Ca and P metabolism in hemodialysis patients with moderate to severe SHPT, as well as intravenous calcitriol administration.
AuthorsH Ito, H Ogata, M Yamamoto, K Takahashi, K Shishido, J Takahashi, S Taguchi, E Kinugasa
JournalClinical nephrology (Clin Nephrol) Vol. 71 Issue 6 Pg. 660-8 (Jun 2009) ISSN: 0301-0430 [Print] Germany
PMID19473635 (Publication Type: Comparative Study, Journal Article, Randomized Controlled Trial)
Chemical References
  • Biomarkers
  • Bone Density Conservation Agents
  • Collagen Type I
  • Parathyroid Hormone
  • Peptides
  • collagen type I trimeric cross-linked peptide
  • Osteocalcin
  • Phosphorus
  • Alkaline Phosphatase
  • Calcitriol
  • 26,26,26,27,27,27-hexafluoro-1,25-dihydroxyvitamin D3
  • Calcium
Topics
  • Administration, Oral
  • Alkaline Phosphatase (blood)
  • Biomarkers (blood)
  • Bone Density Conservation Agents (administration & dosage)
  • Bone and Bones (drug effects, metabolism)
  • Calcitriol (administration & dosage, analogs & derivatives)
  • Calcium (blood)
  • Collagen Type I (blood, drug effects)
  • Cross-Over Studies
  • Female
  • Humans
  • Hyperparathyroidism, Secondary (drug therapy, etiology)
  • Injections, Intravenous
  • Kidney Failure, Chronic (therapy)
  • Male
  • Middle Aged
  • Osteocalcin (blood, drug effects)
  • Parathyroid Hormone (blood)
  • Peptides (blood, drug effects)
  • Phosphorus (blood)
  • Renal Dialysis (adverse effects)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: